Skip to main content
Figure 3 | Molecular Cancer

Figure 3

From: Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and Casein Kinase II inhibition as a potential treatment option

Figure 3

Effect of dasatinib and TBB treatment on cell viability of myxoid liposarcoma cells. 3A) Treatment of myxoid liposarcoma cell cultures with dasatinib leads to maximum 20% decrease in viability at the concentrations higher than 200 nM, though this effect is limited as compared to GIST882. 3B) Treatment with TBB shows a 20% decrease at lower concentrations (20 μM) and a maximum decrease of 75% at 200 μM (cell line 402-92) in the majority of cases. Cell viability with IC50 s as depicted in 3C. 3D) Combined treatment with TBB (at IC50 concentration) and dasatinib (concentrations as in 3A). Jurkat cells where susceptible to TBB, but not to dasatinib. Interestingly, the effect of dasatinib when preceded by TBB was significantly more pronounced than dasatinib in monodrug treatment which means that dasatinib and TBB have an enhanced effect. Graphs show data from four representative experiments. Error bars indicate the standard error of the mean.

Back to article page